文献速递白血病

急性髓系白血病突变特异性靶点的数据挖掘

Data mining for mutation-specific targets in acute myeloid leukemia.
PubMed 文献 · Leukemia · 2019-02-06

本文综述了FDA已批准三种突变特异性靶向药物(米哚妥林用于FLT3突变、恩西地平用于IDH2突变复发/难治病例、艾伏尼布用于IDH1突变病例),合计覆盖高达45%的成人初诊AML。文章总结了可公开访问的组学数据集与生物信息学工具,并举例说明如何通过合成致死、药物重定位、表观遗传亚组和蛋白质组网络挖掘潜在靶点,同时指出优势、局限及验证模型的需求。

要点

  • FDA已批准米哚妥林(FLT3)、恩西地平(IDH2)、艾伏尼布(IDH1)三种突变特异性药物治疗AML。
  • 现有公开数据集包括微阵列基因表达、外显子测序、亚克隆异质性深度测序、RNA测序、DNA甲基化与染色质、胚系数量性状位点。
  • 综述展示了利用合成致死、药物重定位、表观遗传亚组和蛋白质组网络挖掘靶点的示例。

核心结论

  • 三种突变特异性靶向药物为高达45%的成人初诊AML提供突变导向治疗,但临床医生和实验血液学家缺乏时间或培训来访问和分析现有大型复杂数据集。

研究设计与样本

  • 综述总结了当前可用的数据集和生物信息学工具,重点介绍开放、可访问、用户友好且无需编程经验的网络应用。

主要发现

  • FDA批准的突变特异性药物包括米哚妥林(FLT3突变)、恩西地平(IDH2突变复发/难治病例)和艾伏尼布(IDH1突变病例)。
  • 这些药物合计为高达45%的成人初诊AML病例提供突变导向治疗。
  • 可探索的数据集包括微阵列基因表达、外显子测序、亚克隆异质性深度测序、RNA测序(批量和单细胞)、DNA甲基化和染色质、胚系数量性状位点。

局限性

  • 现有验证模型不足,需要更优的模型进行验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Three mutation-specific targeted therapies have recently been approved by the FDA for the treatment of acute myeloid leukemia (AML): midostaurin for FLT3 mutations, enasidenib for relapsed or refractory cases with IDH2 mutations, and ivosidenib for cases with an IDH1 mutation. Together, these agents offer a mutation-directed treatment approach for up to 45% of de novo adult AML cases, a welcome deluge after a prolonged drought. At the same time, a number of computational tools have recently been developed that promise to further accelerate progress in mutation-specific therapy for AML and other cancers. Technical advances together with comprehensively annotated AML tissue banks have resulted in the availability of large and complex data sets for exploration by the end-user, including (i) microarray gene expression, (ii) exome sequencing, (iii) deep sequencing data of sub-clone heterogeneity, (iv) RNA sequencing of gene expression (bulk and single cell), (v) DNA methylation and chromatin, (vi) and germline quantitative trait loci. Yet few clinicians or experimental hematologists have the time or the training to access or analyze these repositories. This review summarizes the data sets and bioinformatic tools currently available to further the discovery of mutation-specific targets with an emphasis on web-based applications that are open, accessible, user-friendly, and do not require coding experience to navigate. We show examples of how available data can be mined to identify potential targets using synthetic lethality, drug repurposing, epigenetic sub-grouping, and proteomic networks while also highlighting strengths and limitations and the need for superior models for validation.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Benard B, Gentles AJ, Köhnke T, et al. Data mining for mutation-specific targets in acute myeloid leukemia. Leukemia. 2019. PMID: 30728456. doi:10.1038/s41375-019-0387-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。